Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (2,615,163)	$ (3,459,754)	$ 3,164,500	$ (12,705,049)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation			311,690	63,791
Depreciation and amortization			816,538	815,285
Loss on disposal of fixed assets	0	(11,000)	0	2,988
Interest added to convertible note payable			0	771,445
Interest expense for reduction in convertible note conversion price			0	4,098,388
Defined benefit plan obligation			0	(73,099)
Amortization of debt discount and warrant modification			35,265	768,000
Fair Value Adjustment of Warrants	(5,000)	(0)	(8,511,000)	(0)
Loss on debt extinguishment	0	0	125,242	0
Changes in operating assets and liabilities:
Accounts receivable, net			(951,818)	(41,322)
Inventories, net			(742,773)	1,035,334
Prepaid expenses and other assets			345,081	151,675
Accounts payable			(2,100,335)	366,162
Accrued expenses and other liabilities			265,001	745,348
Contract liabilities			(92,493)	(240,646)
Other			0	185,000
Net cash used in operating activities			(7,335,102)	(4,056,700)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(38,338)	(34,985)
Proceeds of sales of asset			0	11,000
Capitalization of internal use software costs			0	(72,102)
Net cash used in investing activities			(38,338)	(96,087)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of Series F preferred stock and warrants			8,800,000	4,025,000
Payment to convertible note			0	(325,117)
Proceeds (repayments) on other short-term loans			(135,000)	(4,500)
Issuance costs for sale of Series F preferred stock and warrants			(146,971)	(373,210)
Net cash provided by financing activities			20,384,464	3,607,482
Effects of foreign exchange rates on cash flows			3,538	(8,593)
Net change in cash			13,014,562	(553,898)
Cash at beginning of period			3,613,996	819,024	$ 819,024
Cash at end of period	16,628,558	265,126	16,628,558	265,126	$ 3,613,996
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest cash paid			35,265	852,141
Income taxes paid			0	0
NON-CASH OPERATING AND FINANCING ACTIVITIES:
Issuance of vested restricted Common Stock			157	35
Amended Series B warrants reclassified to stockholders' equity			7,766,000	0
Conversion of Promissory Note and accrued interest to shares of Common Stock	8,612		1,425,606	0
Accrued dividends on Series F Preferred Stock	36,112	47,879	155,800	158,862
Deemed dividends on Series F Preferred Stock, Series B and F Warrants and warrant exchange	208,526	$ 1,450,232	4,942,669	6,707,687
Accrued expense settled with Series B Warrant exercise			350,000	0
Conversion of Series F Preferred Stock into Common Stock [Member]
NON-CASH OPERATING AND FINANCING ACTIVITIES:
Conversion of Preferred Stock Series F to Common Stock			11,501	9,350
Series F Warrants exchanged for shares of Common Stock			11,501	9,350
Conversion of Series F Warrants to Common Stock [Member]
NON-CASH OPERATING AND FINANCING ACTIVITIES:
Conversion of Preferred Stock Series F to Common Stock			149	0
Series F Warrants exchanged for shares of Common Stock			149	0
COVID Loan [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments on COVID loans			(254,885)	(212,392)
Series B Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	6,526,485		8,317,002	0
NON-CASH OPERATING AND FINANCING ACTIVITIES:
Amended Series B warrants reclassified to stockholders' equity	0		7,766,000
Accrued expense settled with Series B Warrant exercise			350,000
Series F Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	$ 3,804,318		$ 3,804,318	$ 497,701